These include chorea associated with HD and tardive dyskinesia as VMAT2 inhibitors are often more effective than the dopamine receptor blocking medications and are not associated with metabolic syndrome nor cause tardive dyskinesia [26]. This evidence concerns the gene SLC18A2 and Huntington disease.